Literature DB >> 17602937

Lifetime risk for developing dyslipidemia: the Framingham Offspring Study.

Mark R Cobain1, Michael J Pencina, Ralph B D'Agostino, Ramachandran S Vasan.   

Abstract

BACKGROUND: High serum low-density lipoprotein(LDL) cholesterol and low high-density lipoprotein (HDL) cholesterol are major vascular risk factors. National surveys indicate that 40% of individuals in the United States have borderline-high LDL cholesterol, and 13-34% have low HDL. The lifetime risk of developing dyslipidemia is unknown, however.
METHODS: We estimated the 10- to 30-year long-term risks of developing "borderline-high" LDL cholesterol (> or =130 mg/dL [3.4 mmol/L]), "high" LDL cholesterol (> or =160 mg/dL [4.1 mmol/L]) and "low" HDL cholesterol (<40 mg/dL [1.0 mmol/L]) in 4701 Framingham Offspring Study participants (53% women) who attended at least 2 examinations between 1971 and 2000. We performed sex-specific analyses (for age groups 30-34, 40-44, 50-54 years), and estimated risks conditional on surviving without the lipid abnormality up to the baseline age. We also estimated risks accounting for baseline prevalence of dyslipidemia (elevated LDL, low HDL).
RESULTS: Over a 30-year period, approximately 6 of 10 participants developed borderline-high LDL, 4 of 10 people developed high LDL, and 2 (women) to 4 (men) of 10 individuals developed low HDL levels; estimates were generally similar for different age groups. Adjustment for baseline prevalence of dyslipidemia increased these estimates: 30-year risks exceeded 80% for borderline-high LDL, 50% for high LDL, and 25% (women) to 65% (men) for low HDL; 20-50% had or developed a low HDL along with a high LDL level. The 30-year estimates approximate the lifetime risk in 50-year-olds.
CONCLUSIONS: The long term risks of developing dyslipidemia are substantial in both sexes, and considerably exceed prevalence estimates from cross-sectional surveys.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17602937     DOI: 10.1016/j.amjmed.2006.12.015

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  3 in total

1.  Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein?

Authors:  Patrick Duriez
Journal:  Curr Atheroscler Rep       Date:  2008-06       Impact factor: 5.113

2.  Predicting the 30-year risk of cardiovascular disease: the framingham heart study.

Authors:  Michael J Pencina; Ralph B D'Agostino; Martin G Larson; Joseph M Massaro; Ramachandran S Vasan
Journal:  Circulation       Date:  2009-06-08       Impact factor: 29.690

3.  Trajectories of Blood Lipid Concentrations Over the Adult Life Course and Risk of Cardiovascular Disease and All-Cause Mortality: Observations From the Framingham Study Over 35 Years.

Authors:  Meredith S Duncan; Ramachandran S Vasan; Vanessa Xanthakis
Journal:  J Am Heart Assoc       Date:  2019-05-29       Impact factor: 5.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.